Compare Freeport-McMoRan Inc (FCX) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Freeport-McMoRan Inc trades at $68.35 (market cap $104.00B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Freeport-McMoRan Inc is far larger — about 106.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Freeport-McMoRan Inc pays a 0.83% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 70 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FCX | MRVI | |
|---|---|---|
Market Cap | $104.00B | $972.90M |
Volume | 7,316,762 | 4,325,710 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $9.00 |
52-Week Low | $38.65 | $2.83 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $110.28B | $1.08B |
Dividend Yield | 0.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $69.62, down 5.01% today, but maintains strong technical momentum with bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Copper demand fundamentals remain robust, driven by AI infrastructure needs, while FCX's expansion projects position it for growth. Analyst consensus remains strongly bullish with a $73.27 price target.
FCX presents a compelling investment case with strong copper demand tailwinds and consistent earnings outperformance. However, rising production costs and a high P/E ratio of 35.5 warrant caution. The stock offers exposure to copper's structural deficit while carrying execution risks from expansion projects and commodity price volatility.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
